SCHEMBL6296951

SCHEMBL6296951

CCCCCC(=O)OCCCC1OC(CO)C(OCc2ccccc2)C(OCc2ccccc2)C1OCc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TACR2 P21452 2/20 0.45
▸ TSHR P16473 4/20 0.45
▸ CYP3A4 P08684 2/20 0.45
▸ MAPK1 P28482 2/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ TDP1 Q9NUW8 2/20 0.45
▸ L3MBTL1 Q9Y468 2/20 0.45
▸ HPSE Q9Y251 1/20 0.40
▸ PTPN1 P18031 1/20 0.40
▸ TP53 P04637 1/20 0.39
▸ PDE4D Q08499 1/20 0.39
▸ LMNA P02545 1/20 0.38
▸ SELP P16109 1/20 0.38
▸ LGALS8 O00214 1/20 0.38
▸ DGKA P23743 1/20 0.37
▸ EPHX2 P34913 1/20 0.36
▸ SSTR1 P30872 1/20 0.36
▸ SSTR2 P30874 1/20 0.36
▸ SSTR4 P31391 1/20 0.36
▸ SSTR3 P32745 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6303446 0.89 PDPK1 (0.42) TACR2TSHRCYP3A4MAPK1ALDH1A1
SCHEMBL6303403 0.85 ALDH1A1 (0.39) TACR2TSHRCYP3A4MAPK1ALDH1A1
SCHEMBL6298852 0.84 SSTR1 (0.48) TACR2TSHRCYP3A4MAPK1ALDH1A1
SCHEMBL6303406 0.82 TSHR (0.39) TACR2TSHRCYP3A4MAPK1ALDH1A1
SCHEMBL8998244 0.79 VEGFA (0.48) LMNASELP
SCHEMBL6304205 0.78 HPGD (0.44) TACR2CYP3A4L3MBTL1LMNA
SCHEMBL15695750 0.78 PTPN1 (0.49) TSHRCYP3A4MAPK1ALDH1A1TDP1
SCHEMBL8998274 0.78 SELP (0.51) ALDH1A1LMNASELP
SCHEMBL6298186 0.77 PDE4D (0.46) TACR2TSHRPTPN1PDE4DSSTR1
SCHEMBL6298896 0.77 PDE4D (0.43) TACR2PTPN1PDE4DSSTR1SSTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6878690-B2 Compounds and methods PHARMAXIS PTY LTD. (AU) 2005-04-12 — — US disclosed
EP-1301522-A4 NOVEL COMPOUNDS AND METHODS PHARMAXIS PTY LTD (AU) 2004-04-14 — — EP disclosed
US-20030176363-A1 Novel compounds and methods PHARMAXIS PTY LTD. (AU) 2003-09-18 — — US disclosed
EP-1301522-A1 NOVEL COMPOUNDS AND METHODS Pharmaxis Pty Ltd (AU) 2003-04-16 — — EP disclosed
WO-2002004472-A1 NOVEL COMPOUNDS AND METHODS PHARMAXIS PTY LTD (AU) 2002-01-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176363-A1 Novel compounds and methods NFATC1, CD4, CCR5 TACR2 4371/4885TSHR 4524/4885CYP3A4 2220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback